Ernexa Therapeutics Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Ernexa Therapeutics Inc. (ERNA) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $766.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2025-03-12
- Ernexa Therapeutics Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2023 was $766.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2023-12-31 | $766.00K 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |